Charles River Laboratories International (NYSE:CRL) Reaches New 52-Week High – Here’s Why

Charles River Laboratories International, Inc. (NYSE:CRL) shares hit a new 52-week high during trading on Tuesday . The company traded as high as $299.99 and last traded at $297.8960, with a volume of 205 shares changing hands. The stock had previously closed at $298.58.

Analyst Ratings Changes

CRL has been the topic of several research reports. BNP Paribas Exane set a $250.00 price target on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Piper Sandler set a $300.00 target price on shares of Charles River Laboratories International in a research report on Monday, August 10th. Mizuho set a $264.00 target price on shares of Charles River Laboratories International in a report on Monday, August 10th. Sanford C. Bernstein set a $250.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. Finally, CLSA cut Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target for the company. in a research note on Monday, July 20th. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of “Moderate Buy” and an average price target of $255.65.

Charles River Laboratories International Stock Performance

The firm has a market cap of $14.26 billion, a price-to-earnings ratio of -61.58, a P/E/G ratio of 3.06 and a beta of 1.38. The stock has a 50 day moving average of $237.19 and a 200 day moving average of $194.41. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. During the same period in the prior year, the company posted $3.12 earnings per share. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 11.35 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In related news, Director Nancy C. Andrews sold 573 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total value of $163,442.52. Following the transaction, the director directly owned 1,438 shares of the company’s stock, valued at $410,175.12. This trade represents a 28.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director James C. Foster sold 28,733 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $275.00, for a total transaction of $7,901,575.00. Following the transaction, the director owned 31,596 shares of the company’s stock, valued at approximately $8,688,900. This represents a 47.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 132,429 shares of company stock worth $32,538,088 in the last three months. Company insiders own 1.30% of the company’s stock.

Institutional Trading of Charles River Laboratories International

Several institutional investors and hedge funds have recently modified their holdings of the business. California State Teachers Retirement System grew its position in Charles River Laboratories International by 22,535.2% in the second quarter. California State Teachers Retirement System now owns 12,895,733 shares of the medical research company’s stock valued at $2,924,623,000 after acquiring an additional 12,838,761 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Charles River Laboratories International by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock worth $1,174,374,000 after acquiring an additional 47,432 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Charles River Laboratories International by 115.8% in the 4th quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after purchasing an additional 1,446,972 shares in the last quarter. State Street Corp grew its holdings in shares of Charles River Laboratories International by 2.2% during the 4th quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock valued at $373,364,000 after purchasing an additional 40,535 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Charles River Laboratories International by 14.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock valued at $285,001,000 after purchasing an additional 210,260 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.